Stock Scorecard



Stock Summary for UroGen Pharma Ltd (URGN) - $13.73 as of 4/19/2024 9:01:51 PM EST

Total Score

9 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for URGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for URGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for URGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for URGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for URGN

Urogen Pharma ( URGN ) Reports Q4 Loss, Tops Revenue Estimates 3/14/2024 1:10:00 PM
Nurix Therapeutics, Inc. ( NRIX ) Surges 5.1%: Is This an Indication of Further Gains? 2/23/2024 11:20:00 AM
Petauri™ Elects William Fleming and James Robinson to Its Board of Directors 12/6/2023 1:00:00 PM
ADC Therapeutics SA ( ADCT ) Reports Q3 Loss, Lags Revenue Estimates 11/7/2023 1:15:00 PM
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors - Eledon Pharma ( NASDAQ:ELDN ) , UroGen Pharma ( NASDAQ:URGN ) 9/11/2023 11:00:00 AM
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors 9/11/2023 11:00:00 AM
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight 8/21/2023 9:01:00 PM
UroGen Pharma ( URGN ) Stock Surges 89% in a Month: Here's Why 8/18/2023 5:40:00 PM
Wall Street Analysts Think Urogen Pharma ( URGN ) Could Surge 89.61%: Read This Before Placing a Bet 8/10/2023 1:55:00 PM
Urogen Pharma ( URGN ) Reports Q2 Loss, Tops Revenue Estimates 8/10/2023 1:15:00 PM

Financial Details for URGN

Company Overview

Ticker URGN
Company Name UroGen Pharma Ltd
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/9/2024

Stock Price History

Last Day Price 13.73
Last Day Price Updated 4/19/2024 9:01:51 PM EST
Last Day Volume 389,406
Average Daily Volume 395,599
52-Week High 24.13
52-Week Low 8.69
Last Price to 52 Week Low 58.00%

Valuation Measures

Trailing PE N/A
Industry PE 100.90
Sector PE 61.34
5-Year Average PE -2.17
Free Cash Flow Ratio 3.31
Industry Free Cash Flow Ratio 12.64
Sector Free Cash Flow Ratio 30.17
Current Ratio Most Recent Quarter 5.42
Total Cash Per Share 4.15
Book Value Per Share Most Recent Quarter -2.01
Price to Book Ratio 16.05
Industry Price to Book Ratio 5.66
Sector Price to Book Ratio 22.08
Price to Sales Ratio Twelve Trailing Months 6.23
Industry Price to Sales Ratio Twelve Trailing Months 5.48
Sector Price to Sales Ratio Twelve Trailing Months 5.19

Share Statistics

Total Shares Outstanding 34,122,100
Market Capitalization 468,496,433
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 6.87%
Reported EPS 12 Trailing Months -3.55
Reported EPS Past Year 0.00
Reported EPS Prior Year -3.73
Net Income Twelve Trailing Months -102,244,000
Net Income Past Year -102,244,000
Net Income Prior Year -109,783,000
Quarterly Revenue Growth YOY 30.10%
5-Year Revenue Growth 136.08%

Balance Sheet

Total Cash Most Recent Quarter 141,500,000
Total Cash Past Year 141,500,000
Total Cash Prior Year 99,964,000
Net Cash Position Most Recent Quarter 42,949,000
Net Cash Position Past Year 42,949,000
Long Term Debt Past Year 98,551,000
Long Term Debt Prior Year 97,537,000
Total Debt Most Recent Quarter 98,551,000
Equity to Debt Ratio Past Year -1.96
Equity to Debt Ratio Most Recent Quarter -1.96
Total Stockholder Equity Past Year -65,212,000
Total Stockholder Equity Prior Year -89,361,000
Total Stockholder Equity Most Recent Quarter -65,212,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.52
MACD Signal -0.69
20-Day Bollinger Lower Band 12.37
20-Day Bollinger Middle Band 15.69
20-Day Bollinger Upper Band 19.01
Beta 1.08
RSI 46.05
50-Day SMA 14.52
200-Day SMA 14.23

System

Modified 4/18/2024 2:01:21 PM EST